RMC is an agressive form of non-clear cell kidney cancer that typically affects young adults and is almost exclusively associated with sickle cell trait.
RMC is resistant to targeted anti-angiogenic therapies, such as sorafenib, sunitinib, and pazopanib, or mechanistic target of rapamycin (mTOR) inhibitors such as everolimus that are used against other renal cell carcinomas. Therefore, these therapies should not be routinely used in patients with RMC.
Renal medullary carcinoma, also known as RMC, is a rare cancer of the kidney that mainly afflicts young people of African descent who carry the sickle cell trait, sickle cell disease, or other sickle hemoglobinopathies that can cause sickling of the red blood cells. Renal cell carcinoma, unclassified with medullary phenotype (RCCU-MP) is a very rare subtype of RMC that occurs in people who do not carry any sickle hemoglobinopathies.